Usefulness of CHA2DS2-Vasc Score for Hyperthyroid Patients with Atrial Fibrillation-Juniper Publishers
JUNIPER PUBLISHERS - OPEN ACCESS JOURNAL OF CARDIOLOGY & CARDIOVASCULAR THERAPY Abstract Anticoagulation in hyperthyroid patients with atrial fibrillation (AF) remains a controversial issue, especially due to the absence of randomized controlled trials defining the impact of warfarin therapy on vascular complications. The current clinical risk score (CHA 2 DS 2 -VASc) seems to be a useful tool for defining anticoagulation among most AF patients. However, AF related to hyperthyroidism may have distinct characteristics that are not considered by clinical risk scores. Notable examples include the younger age of most patients with Graves disease, factors related to hyperthyroidism (severity, time without treatment, T3 predominant thyrotoxicosis), pro-coagulant status due to higher serum thyroxine levels, and the fact that some of the items of the risk score may be reversible with hyperthytroidism treatment. Recent data has shown an incongruence of the CHA 2 DS 2 -VASc...